[Answered]: JS is a 62-year-old man with newly diagnosed…

JS is a 62-year-old man with newly diagnosed stage III diffuse large B-cell lymphoma (DLBCL), International Prognostic Index (IPI) is 3 (aged >60 years, elevated lactate dehydrogenase, Eastern Cooperative Oncology Group [ECOG] performance status 1). JS would like a therapy that is most likely to reduce his chances of requiring additional therapy in the future. According to National Comprehensive Cancer Network (NCCN) Guidelines version 2.2025, which first-line regimen is preferred given JS’s preference? R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) Dose-adjusted R-EPOCH (rituximab plus etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride) pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone) R-mini-CHOP (rituximab and reduced-dose CHOP) Unsure